Norinchukin Bank The Buys 10,055 Shares of Bristol-Myers Squibb (NYSE:BMY)

Norinchukin Bank The grew its position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 11.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 95,991 shares of the biopharmaceutical company's stock after buying an additional 10,055 shares during the period. Norinchukin Bank The's holdings in Bristol-Myers Squibb were worth $5,429,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of BMY. Morse Asset Management Inc raised its position in shares of Bristol-Myers Squibb by 25.0% in the 3rd quarter. Morse Asset Management Inc now owns 10,000 shares of the biopharmaceutical company's stock valued at $517,000 after buying an additional 2,000 shares in the last quarter. Tudor Financial Inc. acquired a new stake in shares of Bristol-Myers Squibb in the 3rd quarter valued at $250,000. Pine Valley Investments Ltd Liability Co increased its stake in shares of Bristol-Myers Squibb by 1.3% in the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 44,897 shares of the biopharmaceutical company's stock valued at $2,323,000 after purchasing an additional 575 shares during the last quarter. World Investment Advisors LLC raised its holdings in shares of Bristol-Myers Squibb by 18.7% during the 3rd quarter. World Investment Advisors LLC now owns 44,106 shares of the biopharmaceutical company's stock worth $2,282,000 after buying an additional 6,954 shares in the last quarter. Finally, Arvest Bank Trust Division acquired a new stake in Bristol-Myers Squibb in the third quarter valued at about $1,724,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Insider Buying and Selling at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 1,823 shares of the stock in a transaction dated Friday, February 14th. The shares were bought at an average price of $54.84 per share, with a total value of $99,973.32. Following the completion of the transaction, the executive vice president now directly owns 63,932 shares in the company, valued at approximately $3,506,030.88. This trade represents a 2.94 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.09% of the company's stock.

Analyst Upgrades and Downgrades

BMY has been the topic of a number of research analyst reports. UBS Group reduced their price target on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research note on Friday, April 11th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $55.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday. Wells Fargo & Company increased their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a research note on Friday, February 7th. Piper Sandler started coverage on shares of Bristol-Myers Squibb in a report on Tuesday. They set an "overweight" rating and a $65.00 target price on the stock. Finally, Citigroup boosted their price objective on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a research note on Tuesday, January 28th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating, five have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $58.00.

Bristol-Myers Squibb Stock Up 0.3 %

Shares of BMY stock traded up $0.13 during trading hours on Thursday, reaching $48.66. The company had a trading volume of 20,574,936 shares, compared to its average volume of 13,088,652. The company has a market cap of $99.01 billion, a price-to-earnings ratio of -11.01, a price-to-earnings-growth ratio of 2.07 and a beta of 0.41. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.33. The business has a fifty day simple moving average of $56.60 and a 200-day simple moving average of $56.54.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.55 by $0.25. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The firm had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. During the same quarter in the prior year, the business posted ($4.40) EPS. On average, research analysts expect that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Friday, April 4th will be paid a $0.62 dividend. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 5.10%. Bristol-Myers Squibb's payout ratio is presently -56.11%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.